The multiple cellular targets affected by proteasome inhibition implicate a potential role for
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …

Background Proteasome inhibition results in antitumor activity through various mechanisms,
including disruption of cell cycle progression and control, induction of apoptosis, and …

Bortezomib is a highly selective inhibitor of the 26S proteasome and has been approved for
clinical use in the treatment of relapsing and refractory multiple myeloma and mantle cell …

The proteasome plays a critical role in the regulation of many cellular processes, including
the cell cycle and tumor growth. The proteasome inhibitor bortezomib has recently been …

Many cellular processes converge on the proteasome, and its key regulatory role is
increasingly being recognized. Proteasome inhibition allows the manipulation of many …

The ubiquitin–proteasome system has become a promising molecular target in cancer
therapy due to its critical role in cellular protein degradation, interaction with cell cycle and …

The proteasome is a multiprotease complex that degrades the majority of cellular proteins in
a highly regulated manner. The elimination of many key proteins by the proteasome is …

Bortezomib, a proteasome inhibitor, has been clinically approved for the treatment of
myeloma and lymphoma. Here, we report a differential effect of bortezomib on apoptosis in …

The proteasome is responsible for the degradation of intracellular proteins, including several
involved in cell cycle control and the regulation of apoptosis. Preclinical studies have shown …

Proteasomes have a fundamental function since they degrade numerous different proteins,
including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel …